文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向磷脂酰肌醇蛋白聚糖3的放射性药物用于肝细胞癌:分子平台综述

Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms.
PubMed 文献 · EJNMMI Res · 2026-05-26

该综述以分子平台为中心,比较了针对磷脂酰肌醇蛋白聚糖3(GPC-3)的多种靶向载体在肝细胞癌中的应用。GPC-3放射性药物从清除缓慢的单克隆抗体发展到快速排泄的抗体片段、肽等平台,当前通过化学修饰优化药代动力学,以兼顾同日显像的诊断信噪比与靶向放射治疗所需的肿瘤滞留。未来临床转化需进一步探索最佳药代动力学,并探索α放射性核素、多靶点策略及与免疫治疗协同等方向。

要点

  • GPC-3放射性药物平台从单抗向抗体片段、肽等快速排泄载体演进。
  • 化学修饰如白蛋白结合基团、PEG化、环化用于优化药代动力学。
  • 未来方向包括α放射性核素、多靶点及与免疫检查点抑制剂协同。

核心结论

  • 未来临床转化需进一步探索最佳药代动力学特性,在诊断与治疗能力之间取得更好平衡,以推动GPC-3诊疗一体化进入常规临床实践。
  • 转向更强效的α放射性核素、从单靶点转向多靶点策略(如GPC-3与前列腺特异性膜抗原PSMA)以及放射性核素治疗与免疫治疗(如免疫检查点抑制剂)协同,有望克服肿瘤异质性并延长患者生存。

研究设计与样本

  • 综述以平台为中心,比较针对GPC-3设计的多种分子靶向载体。

主要发现

  • GPC-3放射性药物的发展从清除缓慢的单克隆抗体演进到快速排泄的抗体片段、肽和其他有前景的平台。
  • 早期平台选择面临分子大小与肿瘤滞留之间的妥协。
  • 当前策略倾向于通过化学修饰优化药代动力学特征,包括应用白蛋白结合基团、PEG化(聚乙二醇修饰)、环化以及整合这些策略。
  • 这些工程方法旨在为诊断提供同日显像的最佳信噪比,同时确保靶向放射核素治疗所需的持续肿瘤滞留。

临床怎么用

  • 在GPC-3靶向诊疗一体化中,需根据诊断同日显像与治疗肿瘤滞留的需求权衡选择分子平台。
  • 可利用白蛋白结合、PEG化、环化等化学修饰策略优化候选药物的药代动力学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatocellular carcinoma (HCC) is characterized by high heterogeneity, making early diagnosis and systemic therapy challenging. Glypican-3 (GPC-3) targeted radiopharmaceuticals are promising tools for HCC. This review summarizes the development of this field from a platform-centric perspective, comparing various molecular targeting vectors designed against GPC-3. MAIN BODY: The development of GPC-3 radiopharmaceuticals has evolved from slow-clearing monoclonal antibodies (mAbs) to rapidly excreted antibody fragments, peptides and other promising platforms. Early platform selection faced a compromise between molecular size and tumor retention. Current strategies tend to optimize pharmacokinetic profiles through chemical modifications, including the application of albumin-binding groups, PEGylation (polyethylene glycol modification), cyclization and integrating these strategies. These engineering approaches aim to provide an optimal signal-to-noise ratio in same-day imaging for diagnosis, while ensuring sustained tumor retention required for targeted radionuclide therapy. CONCLUSION: Future clinical translation will require further exploration of optimal pharmacokinetic properties to achieve a better balance between diagnostic and therapeutic capabilities, which is essential to promote GPC-3 theranostics into routine clinical practice. Furthermore, emerging strategies such as shifting towards more potent alpha-radionuclides; moving from single-targeting to multi-targeting strategies, such as GPC-3 and prostate-specific membrane antigen (PSMA); and synergizing radionuclide therapy with immunotherapy (e.g., immune checkpoint inhibitors) are expected to become key to overcoming tumor heterogeneity and prolonging patient survival.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Sun Y, Qiu L. Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms. EJNMMI Res. 2026. PMID: 42192025. doi:10.1186/s13550-026-01454-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。